Welcome to our dedicated page for Theravance Bioph news (Ticker: TBPH), a resource for investors and traders seeking the latest updates and insights on Theravance Bioph stock.
Theravance Biopharma, Inc. reports biopharmaceutical developments centered on YUPELRI® (revefenacin) inhalation solution, an FDA-approved maintenance treatment for chronic obstructive pulmonary disease. Company updates commonly address YUPELRI collaboration revenue, U.S. net sales recognized by Viatris, hospital-channel demand, brand profitability, and intellectual-property matters related to generic challenges.
Theravance news also covers portfolio changes following the Phase 3 CYPRESS study of ampreloxetine in symptomatic neurogenic orthostatic hypotension due to multiple system atrophy, including the decision to wind down that program. Recurring corporate updates include cost-reduction actions, operating expense trends, TRELEGY milestone economics reported by GSK, cash position, and governance or capital-allocation reviews.
Theravance Biopharma (NASDAQ: TBPH) announced its participation in two upcoming investor conferences. The first is the Morgan Stanley 18th Annual Global Healthcare Conference on September 14, 2020, at 1:30 p.m. ET, followed by the H.C. Wainwright 22nd Annual Global Investment Conference on September 15, 2020, at 9:30 a.m. ET. Webcast presentations will be accessible on the company's website under the "Investors" section, with replays available for at least 30 days. Theravance specializes in organ-selective medicines targeting inflammation and immunology.
Theravance Biopharma (NASDAQ: TBPH) reported Q2 2020 revenue of $15.0 million, down $11.1 million year-over-year, primarily due to decreased collaboration and licensing revenue. Operating loss was $72.2 million, or $55.6 million without share-based compensation. Cash reserves stood at $438.3 million. The company noted a market share increase for YUPELRI despite COVID-19 challenges and aims for it to be cash-flow positive by year-end. Clinical programs for ampreloxetine and TD-1473 were delayed, but progress continues with new COVID-19 related candidate TD-0903.
Theravance Biopharma (NASDAQ: TBPH) announced the appointment of Deepika R. Pakianathan, Ph.D., to its Board of Directors as of July 2, 2020. Dr. Pakianathan has extensive experience in the biotechnology sector, previously serving as a Managing Member at Delphi Ventures and holding key positions at J.P. Morgan. Her expertise is expected to strengthen the board's capability to navigate the company's growth. CEO Rick E Winningham expressed confidence in Dr. Pakianathan's ability to enhance the company's strategic direction during this pivotal phase.
Theravance Biopharma (NASDAQ: TBPH) announced the first patient has been dosed in a Phase 2 study of TD-0903, a lung-selective JAK inhibitor targeting hospitalized COVID-19 patients with Acute Lung Injury (ALI). The study aims to assess the treatment's safety and clinical response in patients showing hypoxia. Following a successful Phase 1 study in healthy volunteers, the Phase 2 trial will occur across the UK and other European nations. TD-0903 is designed to inhibit the cytokine storm linked to ALI, potentially preventing progression to Acute Respiratory Distress Syndrome (ARDS).